×
0 0 0 0.122082585278276 0.118491921005386 0.0323159784560143 0.00538599640933577 0.00538599640933577
Stockreport

Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs

GALECTIN THERAPEUTICS (GALT)  More Company Research Source: GlobeNewswire
Last galectin therapeutics earnings: 8/14 08:00 am Check Earnings Report
PDF NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis (NASH) cirrhosis and cancer, announced today that the company has received two new patents in China and two new patents in Japan for the Company's lead compound, GR-MD-02. "As the second and third largest pharmaceutical markets in the world, having strong patent protection for GR-MD-02 in China and Japan is strategically important to our company, particularly now that we have positive clinical data in both NASH cirrhosis and cancer immunotherapy,” said Peter G. Traber, M.D., chief executive officer and chief medical officer of Galectin Therapeutics and inventor on the patents. “As we consider partnerships to bring GR-MD-02 to the Asia markets for NASH cirrhosis cancer immunotherapies, and potentially other disorders, these patents will allow us and our future partners to take full advan [Read more]

IMPACT SNAPSHOT EVENT TIME: GALT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GALT alerts

from News Quantified
Opt-in for
GALT alerts

from News Quantified